Mechanisms of gestagen therapy on endometrial cancer.
孕激素治疗子宫内膜癌的机制。
基本信息
- 批准号:01570916
- 负责人:
- 金额:$ 1.41万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1989
- 资助国家:日本
- 起止时间:1989 至 1991
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
An attempt was made to clarify the mechanisms of gestagen therapy on endometrial cancer or breast cancer.Mammary tumor was. induced in female Sprague-Dawley rats by oral administration of 7, 12-dimethybenz[a]anthracene(DMBA). Histologically, the induced mammary tumors were divided into 7 types such as well differentiated adenocarcinoma, moderately differentiated adenocarcinoma and so on. Estrogen receptor(ER)and progesterone receptor(PR)were positively determined in 43(87.8%)and 34(69.4%), respectively, out of 49 samples by the dextran-coated charcoal(DCC)method. A portion of DMBA-induced mammary tumor was transplanted subcutaneously into nude mice in 38 samples. All but one sample which contains neither ER nor PR, could not make tumors. The tumors which were autoimplanted into subcutaneous tissue of the rats did not develop.The primary culture of the tumor have been carried out in 35 times. Though the excellent cell growth of the epithelial cells and fibroblastic cells were seen at the primary stage, no cell lines have been established, because the cell numbers had been tapering at each subculture. We investigated the effects of medroxyprogesterone acetate(MPA)on the tumor developed in nude mice. No apparent antitumor effects were seen. We also investigated antitumor effects of MPA in vitro using the cell strain. There were no difference between the MPA group and the control group.
试图阐明孕激素治疗子宫内膜癌或乳腺癌的机制。乳腺肿瘤。通过口服 7, 12-二甲基苯并[a]蒽 (DMBA) 在雌性 Sprague-Dawley 大鼠中诱导。组织学上将诱发的乳腺肿瘤分为高分化腺癌、中分化腺癌等7种类型。右旋糖酐包被炭(DCC)法检测49份样品中雌激素受体(ER)和孕激素受体(PR)分别呈阳性43份(87.8%)和34份(69.4%)。将DMBA诱导的乳腺肿瘤的一部分皮下移植到38个裸鼠样本中。除一份样品外,所有样品均不含 ER 和 PR,均不能产生肿瘤。自体植入大鼠皮下组织的肿瘤未发育,肿瘤原代培养35次。尽管在初级阶段观察到上皮细胞和成纤维细胞的良好细胞生长,但尚未建立细胞系,因为细胞数量在每次传代培养中逐渐减少。我们研究了醋酸甲羟孕酮(MPA)对裸鼠肿瘤生长的影响。没有看到明显的抗肿瘤作用。我们还使用细胞株研究了 MPA 的体外抗肿瘤作用。 MPA组和对照组之间没有差异。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NISHIDA Masato其他文献
NISHIDA Masato的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NISHIDA Masato', 18)}}的其他基金
Chemosensitivity test using immunoprotected culture system in vivo.
使用体内免疫保护培养系统进行化学敏感性测试。
- 批准号:
07671765 - 财政年份:1995
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Chemosensitivity of gynecologic malignancies revealed by disease oriented screening system.
疾病导向筛查系统揭示妇科恶性肿瘤的化学敏感性。
- 批准号:
05671352 - 财政年份:1993
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Elucidating the role of the SWI/SNF complex in mediating hormone therapy resistance in breast cancer
阐明 SWI/SNF 复合物在介导乳腺癌激素治疗耐药中的作用
- 批准号:
10199597 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Elucidating the role of the SWI/SNF complex in mediating hormone therapy resistance in breast cancer
阐明 SWI/SNF 复合物在介导乳腺癌激素治疗耐药中的作用
- 批准号:
10410445 - 财政年份:2021
- 资助金额:
$ 1.41万 - 项目类别:
Study of the mechanism underlying the acquired hormone therapy resistance in breast cancer
乳腺癌获得性激素治疗耐药机制研究
- 批准号:
20H03748 - 财政年份:2020
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Acquired resistance to hormone therapy of breast cancer by mitochondrial reactive oxygen species
线粒体活性氧对乳腺癌激素治疗的获得性耐药
- 批准号:
17K10551 - 财政年份:2017
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of molecular mechanisms of a lipid mediator in resistance of breast cancer hormone therapy and its clinical significance
脂质介质抵抗乳腺癌激素治疗的分子机制及其临床意义的阐明
- 批准号:
17K10538 - 财政年份:2017
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Enzymes of the sphingolipid metabolism as potential prognostic markers for breast cancer patients - and the impact of a anti-hormone therapy
鞘脂代谢酶作为乳腺癌患者潜在的预后标志物 - 以及抗激素治疗的影响
- 批准号:
274771287 - 财政年份:2015
- 资助金额:
$ 1.41万 - 项目类别:
Research Grants
Defining Mechanisms of Hormone Therapy Breast Cancer Risk Reduction and Biomarkers of Response
确定激素治疗降低乳腺癌风险的机制和反应生物标志物
- 批准号:
MR/M019039/1 - 财政年份:2015
- 资助金额:
$ 1.41万 - 项目类别:
Fellowship
Possible mechanisms for induced effect of gestagens to breast cancer risk at hormone therapy in contraception and postmenopause
避孕和绝经后激素治疗中孕激素对乳腺癌风险产生影响的可能机制
- 批准号:
249491325 - 财政年份:2014
- 资助金额:
$ 1.41万 - 项目类别:
Research Grants
Establishment of Novel Anti-Hormone Therapy of Breast Cancer based on the Inhibition of Uptake Transporter of Conjugated Estrogen by Cancer Cells.
基于抑制癌细胞摄取结合雌激素转运蛋白建立新型乳腺癌抗激素疗法。
- 批准号:
17390046 - 财政年份:2005
- 资助金额:
$ 1.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Project 2: Inflammation-Based Mechanisms of Hormone Therapy Resistance in Breast Cancer
项目2:基于炎症的乳腺癌激素治疗耐药机制
- 批准号:
10011766 - 财政年份:1997
- 资助金额:
$ 1.41万 - 项目类别: